A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Clinical trial NCT03744676 · COMPLETED

Trial details

NCT number: NCT03744676
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Non-Hodgkin Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms Neoplasms by Histologic Type Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Disorder

Start date: 2018-11-29
Primary completion: 2023-09-22
Enrollment: 104

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.